Author:
Qin Rong-Sheng,Zhang Zhen-Hua,Zhu Neng-Ping,Chen Fei,Guo Qian,Hu Hao-Wen,Fu Shao-Zhi,Liu Shan-Shan,Chen Yue,Fan Juan,Han Yun-Wei
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Reference48 articles.
1. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004;4:423–36.
2. Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60(7):1878–86.
3. Pasquier E, Kavallaris M, Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010;7:455–65.
4. Camerini A, Puccetti C, Amoroso D, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.
5. Mencoboni M, Filiberti RA, Taveggia P, et al. Safety of first-line chemotherapy with metronomic single-agent oral Vinorelbine in elderly patients with NSCLC. Anticancer Res. 2017;37(6):3189–94.
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献